Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ECOR vs RCEL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
RCEL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)
RCEL Overall Winner
6-Pillar Tally: ECOR 2 – 3 RCEL (1 Tie)
Matrix Metrics: ECOR 3 – 7 RCEL
As of Nov 20, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over electroCore, Inc. (ECOR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ECOR carries a Unified Composite Score of 44.5/100 (HOLD) at $4.42 (N/M Forward P/E, -33.1% operating margin), whereas RCEL carries 45.6/100 (HOLD) at $15.62 (10.3x Forward P/E, -33.9% operating margin).
- Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.3); meanwhile RCEL trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ECOR vs RCEL
ECOR
electroCore, Inc. Common Stock
$4.42
-8.87% 1D
Market Cap
$44.7M
TTM Revenue
$38M
Forward P/E
N/M
Beta / 30D Vol
1.55β · 155% Vol
Unified Composite Score
44.5
HOLD
Tech 30.0
Fund 60.0
Flow 50.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
RCEL
Head-to-Head Winner
Avita Medical, Inc. Common Stock
$15.62
-2.31% 1D
Market Cap
$506.7M
TTM Revenue
$85M
Forward P/E
10.3x
Beta / 30D Vol
1.54β · 65% Vol
Unified Composite Score
45.6
HOLD
Tech 32.0
Fund 44.0
Flow 69.0
Mom 31.1
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (ECOR 2 – 3 RCEL)
1. Valuation Multiples
RCEL
Forward P/E
N/M
10.3x
Trailing P/E
N/M
10.3x
PEG Ratio
N/M
N/M
EV / Revenue
1.3x
6.4x
2. Growth & Scale
RCEL
Revenue Growth (YoY)
+11.5%
+53.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$38M
$85M
Market Cap
$44.7M
$506.7M
3. Profitability & Quality
ECOR
Gross Margin
87.7%
82.4%
Operating Margin
-33.1%
-33.9%
Net Profit Margin
-33.5%
-42.6%
Return on Equity (ROE)
-478.7%
-1746.3%
4. Balance Sheet & Cash Flow
ECOR
Cash Generation (TTM)
-$6.9M
-$20M
Cash Flow Margin
-18.1%
-23.6%
Net Cash / Leverage
$4.6M Net Debt
$37M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
RCEL
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
N/A (N/A)
84.7% (6th %ile)
Put/Call OI Skew
N/A
0.18x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ECOR (3) vs RCEL (7)| Institutional Metric | ECOR | RCEL | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $44.7M | $506.7M | RCEL | |
| Trailing P/E Ratio | N/M | 10.3x | RCEL | |
| Forward P/E Ratio | N/M | 10.3x | RCEL | |
| Revenue Growth (YoY) | +11.5% | +53.1% | RCEL | |
| Operating Margin (TTM) | -33.1% | -33.9% | ECOR | |
| Net Profit Margin | -33.5% | -42.6% | ECOR | |
| Return on Equity (ROE) | -478.7% | -1746.3% | ECOR | |
| 52-Week Range Position | 6% ($4–$13) | 82% ($3–$18) | RCEL | |
| Beta / 30D Volatility | 1.55β · 155% Vol | 1.54β · 65% Vol | RCEL | |
| Unified Institutional Score | 44.5 / 100 (HOLD) | 45.6 / 100 (HOLD) | RCEL | |
| Trailing 12M Revenue (USD) | $38M | $85M | Scale | |
| Gross Profit Margin (TTM) | 87.7% | 82.4% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 1.3x EV/Rev | N/M PEG · 6.4x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$6.9M ($4.6M Net Debt) | -$20M ($37M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
RCEL +41.65 pp
3M Horizon
RCEL +111.82 pp
6M Horizon
RCEL +274.78 pp
1Y Horizon
RCEL +304.87 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ECOR Revenue | RCEL Revenue | ECOR Op. Margin | RCEL Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | $0M | -5494.1% | -1489.9% | RCEL |
| FY2019 | $0M | $10M | -1928.2% | -466.4% | RCEL |
| FY2020 | $0M | $10M | -707.9% | -299.2% | RCEL |
| FY2021 | $10M | $30M | -367.7% | -90.8% | RCEL |
| FY2022 | $10M | $30M | -266.2% | -79.9% | RCEL |
| FY2023 | $20M | $50M | -120.2% | -85.1% | RCEL |
| FY2024 | $30M | $60M | -48.3% | -88.1% | ECOR |
| FY2025 | $30M | $70M | -41.1% | -59.4% | ECOR |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ECOR
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ECOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
RCEL
CONSOLIDATION
Current IV
84.7%
IV Percentile
6th %ile
Put/Call OI Skew
0.18x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact RCEL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ECOR Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
RCEL Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ECOR vs RCEL Key Questions & Quantitative Answers
As of Nov 20, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over electroCore, Inc. (ECOR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ECOR carries a Unified Composite Score of 44.5/100 (HOLD) at $4.42 (N/M Forward P/E, -33.1% operating margin), whereas RCEL carries 45.6/100 (HOLD) at $15.62 (10.3x Forward P/E, -33.9% operating margin). Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.3); meanwhile RCEL trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RCEL leads the Growth & Scale pillar: ECOR posts +11.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (87.7% gross margin, -33.1% operating margin), compared with RCEL at +53.1% YoY revenue growth and +0.0% YoY earnings growth on $85M TTM revenue (82.4% gross margin, -33.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ECOR cumulative revenue shifted +200.0% while RCEL shifted +600.0%. In operating R&D and SG&A reinvestment, ECOR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RCEL.
RCEL screens cheaper on headline valuation multiples. ECOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-18.1% FCF margin), whereas RCEL trades at 10.3x Forward P/E, 10.3x Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-23.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ECOR (-478.7% ROE) versus RCEL (-1746.3% ROE) capital efficiency.
In options market volatility and institutional positioning, ECOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 155% Vol realized risk). By comparison, RCEL carries 84.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.54β · 65% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
RCEL vs ECOR · Reverse Pair
ECOR vs PRPO
· Sector Peer
RCEL vs SIBN
· Sector Peer
RCEL vs ORIC
· Sector Peer
RCEL vs PROF
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma